Stock Quote
Human Genome Sciences, Inc. (HGSI.O) (Consolidated Issue listed on NASDAQ Global Market)
$27.96
25 Nov 2009
+0.14%
$27.96
--
2,670,918
$27.96
$27.96
$29.48
$0.45
5.30
4,685,441
HGSI.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Karabelas, Argeris | Chairman of the Board | -- |
| Watkins, H. Thomas | President, Chief Executive Officer, Director | 3,427,740 |
| Barabe, Timothy | Chief Financial Officer, Senior Vice President | 968,958 |
Profile
Human Genome Sciences (HGS)is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. Albuferon and LymphoStat-B are... Full Description
Company Address
Human Genome Sciences, Inc.
14200, Shady Grove Road
Rockville MD 20850-7464
P: +1301.3098504
F: +1301.3098512
14200, Shady Grove Road
Rockville MD 20850-7464
P: +1301.3098504
F: +1301.3098512
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $63.30 | +0.12 |
| GlaxoSmithKline plc | £1,266.50 | -5.50 |
| Genentech, Inc. | -- | -- |
| HGSI.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 13.09 |
| P/S(TTM) | 19.57 | 31.15 |
| ROI(TTM) | -5.39 | 2.44 |
| ROE(TTM) | -97.57 | 3.70 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -0.23 |
| EPS Est. (Current Year) | -0.03 |
| Total Revenue | $18.83M |
| Net Income | $-49.00M |
| EPS | $-0.32 |
